<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>The high infectiousness and contagiousness of the SARS-CoV-2, as well as the alarmingly severe course of COVID-19, inspired research teams from around the world to begin an urgent search for effective methods to neutralize the new pathogen. The mRNA vaccine Comirnaty was the first conditionally licensed vaccine against SARS-CoV-2. Its key ingredient is a fragment of matrix RNA obtained by <italic>in vitro</italic> transcription that corresponds to the sequence that encodes the spike protein (S protein) of the SARSCoV-2. Today, it is well established that in the face of the continued evolution of the SARS-CoV-2, the effectiveness of the vacci-nation in the core regimen is not sufficient to prevent infection. However, the sustained high level of vaccine protection against severe forms of COVID-19 can significantly reduce hospitalizations and deaths. In addition, the documented risk of serious adverse events following each dose of the vaccine appears relatively small compared to the potential health consequences of COVID-19 infection. This article presents scientific studies describing the role of the Comirnaty vaccine in the prevention of COVID-19 infection and severity.</p>
</abstract>

The high infectiousness and contagiousness of the SARS-CoV-2, as well as the alarmingly severe course of COVID-19, inspired research teams from around the world to begin an urgent search for effective methods to neutralize the new pathogen. The mRNA vaccine Comirnaty was the first conditionally licensed vaccine against SARS-CoV-2. Its key ingredient is a fragment of matrix RNA obtained by in vitro transcription that corresponds to the sequence that encodes the spike protein (S protein) of the SARSCoV-2. Today, it is well established that in the face of the continued evolution of the SARS-CoV-2, the effectiveness of the vacci-nation in the core regimen is not sufficient to prevent infection. However, the sustained high level of vaccine protection against severe forms of COVID-19 can significantly reduce hospitalizations and deaths. In addition, the documented risk of serious adverse events following each dose of the vaccine appears relatively small compared to the potential health consequences of COVID-19 infection. This article presents scientific studies describing the role of the Comirnaty vaccine in the prevention of COVID-19 infection and severity.

Efficacy, effectiveness and safety of Comirnaty vaccine in the prevention of symptomatic and asymptomatic SARS-CoV-2 infections

Pomeranian Medical University in Szczecin

Department of Biochemistry and Medical Chemistry

Pomeranian Journal of Life Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

The high infectiousness and contagiousness of the SARS-CoV-2, as well as the alarmingly severe course of COVID-19, inspired research teams from around the...

Efficacy, effectiveness and safety of Comirnaty vaccine in the prevention of symptomatic and asymptomatic SARS-CoV-2 infections

Pubblicato online: 02 set 2022

Pagine: 25 - 29

DOI: https://doi.org/10.21164/pomjlifesci.830

Parole chiave
SARS-CoV-2, COVID-19, Comirnaty, Pfizer/BioNTech, mRNA vaccine, vaccine efficacy, vaccine effectiveness, vaccine safety

© 2022 Mikołaj Chlubek et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Efficacy, effectiveness and safety of Comirnaty vaccine in the prevention of symptomatic and asymptomatic SARS-CoV-2 infections

Pubblicato online: 02 set 2022

Pagine: 25 - 29

DOI: https://doi.org/10.21164/pomjlifesci.830

Parole chiaveSARS-CoV-2, COVID-19, Comirnaty, Pfizer/BioNTech, mRNA vaccine, vaccine efficacy, vaccine effectiveness, vaccine safety

© 2022 Mikołaj Chlubek et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Parole chiave
SARS-CoV-2, COVID-19, Comirnaty, Pfizer/BioNTech, mRNA vaccine, vaccine efficacy, vaccine effectiveness, vaccine safety